Revance Therapeutics Inc. (RVNC)
NASDAQ: RVNC
· Real-Time Price · USD
3.65
0.00 (0.00%)
At close: Feb 05, 2025, 3:59 PM
0.00% (1D)
| Bid | 3.65 |
| Market Cap | 381.02M |
| Revenue (ttm) | 243.9M |
| Net Income (ttm) | -287.5M |
| EPS (ttm) | -3.34 |
| PE Ratio (ttm) | -1.092814371257485 |
| Forward PE | -16.59 |
| Analyst | Hold |
| Ask | 3.66 |
| Volume | 0 |
| Avg. Volume (20D) | 2,958,312 |
| Open | 3.65 |
| Previous Close | 3.65 |
| Day's Range | 3.65 - 3.65 |
| 52-Week Range | 2.30 - 7.56 |
| Beta | 0.95 |
About RVNC
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RVNC
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RVNC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
Revance Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
5 months ago
Revance shares are trading lower after the company announced an amended and restated merger agreement with Crown Laboratories, under which Crown will commence a tender offer to acquire all outstanding shares of Revance's common stock for $3.10 per share in cash.
2 months ago · accessnewswire.com
March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNCNEW YORK, NY / ACCESS Newswire / March 3, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal secur...
